All News
Pascual et al. Anti-TIF1gamma and cancer risk in DM and non-DM. Cancer in 60% of DM and 21% of non-DM patients with Anti-TIF1gamma https://t.co/OxKdlmDBBD
Richard Conway RichardPAConway ( View Tweet)
Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu
Richard Conway RichardPAConway ( View Tweet)
Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074
Robert B Chao, MD doctorRBC ( View Tweet)
Vadillo et al. Clinical course in IPAF (ping @leticiakawano ) . Most frequent females in 60s. Arthritis, raynauds most common features. Most NSIP. 50% PFT deterioration 16 months. UIP, baseline fibrosis, mod/high ANA titre assoc progression @RheumNow #EULAR2022 POS1427 https://t.co/qk9zK90Wuk
Richard Conway RichardPAConway ( View Tweet)
Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts.
@RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC
Robert B Chao, MD doctorRBC ( View Tweet)
Rahman et al. 2 year results on dactylitis/enthesitis from Discover-2 study guselkumab. Sustained improvements seen over time @RheumNow #EULAR2022 POS1028 https://t.co/VZhw6g4kCB
Richard Conway RichardPAConway ( View Tweet)
“I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have other options.” – Prof. I McGinnes #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6
Richard Conway RichardPAConway ( View Tweet)
Kimme Hyrich:
💉Risks of autoimmune flare is very low (3-5%)
💉Flares are mild when present after COVID-19 vaccination
Most unvaccinated patients did NOT identify as "anti-vax"... number 1 reason is concerns about their health
#EULAR2022 @RheumNow @rheum_covid https://t.co/Ogn0raifPd
Eric Dein ericdeinmd ( View Tweet)
Karpouzas et al. ORAL Surveillance analysis. MACE, VTE, infections higher in those with acute and cumulative disease activity as measured by CDAI. @RheumNow #EULAR2022 POS0519 https://t.co/CtlISf2rxr
Richard Conway RichardPAConway ( View Tweet)
#SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should be vaccinated: K Hyrich @eular_org #EULAR2022 @RheumNow session: Types if vaccine and how they work. https://t.co/Dkl8mTQpkj
Janet Pope Janetbirdope ( View Tweet)
#EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus & disease understanding. Tour de force from blood IFN signature use to Plasmablast (correlate with activity inc. in African) and Neutrophil/myeloid signatures (nephritis) @RheumNow https://t.co/tiX55ARDvC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Rojas-Gimenez et al After adjusting for age, smoking, ACPA. Male sex (OR 4.2) and longer time of having RA (OR 1.08) associated with ILD @RheumNow #EULAR2022 POS0619 https://t.co/kzG76Qwe52
Richard Conway RichardPAConway ( View Tweet)
Does MTX have an impact on UST-immunogenicity in PsA?
Post-hoc analysis from UST RCT in 110+ pts
No difference in ADA rates & concentrations between
MTX and non-MTX groups and
ADA not associated w/ decreased UST levels
POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT
Aurelie Najm AurelieRheumo ( View Tweet)
Don’t forget about the benefits of vaccines for diseases other than #COVID19 – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/86e93ugoBQ
TheDaoIndex KDAO2011 ( View Tweet)
Pneumonia and influenza risk higher in patients with rheumatic disease!
Influenza Relative Risk: 1.2-3.3
Pneumonia RR: shown to be up to 14.2 in SLE!
💉Vaccinations work!
#EULAR2022 @Rheumnow @rheum_covid https://t.co/gvD1PaLQRe
Eric Dein ericdeinmd ( View Tweet)
Sanchez-Martin et al. Tocilizumab in newly diagnosed vs refractory GCA. 471 patients. Appears of relatively similar efficacy in both groups. Surprising that the difference is not greater given refractory GCA inherently more complex @RheumNow #EULAR2022 POS0817 https://t.co/HEWzYCz9YD
Richard Conway RichardPAConway ( View Tweet)
Proof that vaccines work in our rheum patients; reduction in hospitalization, ICUs, death – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/u8PWvgfdiC
TheDaoIndex KDAO2011 ( View Tweet)
#EULAR2022:
Kimme Hyrich: Think about Herpes zoster risk in ALL rheumatic disease patients (not just, but particularly with JAKs).
💉Avoid Zostavax (Live) in patients on immunosuppression
💉Warn side effects are common with Shingrix
@RheumNow @rheum_covid https://t.co/w7p4oHuqL9
Eric Dein ericdeinmd ( View Tweet)
2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt
Richard Conway RichardPAConway ( View Tweet)